ClinicalTrials.gg
TerminatedNCT00263965Updated Mar 17, 2008

ARAMIS: Actions of tesaglitazaR on fAt Metabolism and Insulin Sensitivity

A Phase 2 interventional study of Tesaglitazar and Metformin in Type 2 Diabetes, sponsored by AstraZeneca. Terminated at 3 sites in 3 countries. Open to participants aged 30 Years to 70 Years. Per ClinicalTrials.gov, last updated 2008-03-17.

Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment

Why this study was terminated
The development program has been terminated

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
105
Allocation
Randomized
Ages
30 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 15 studies testing tesaglitazar in Diabetes Mellitus, Type 2 — none open to participants now, none under way, none of them phase 3. tesaglitazar · Diabetes Mellitus, Type 2.

Enrollment
13th of 15
105 · median 500
Started
2005
with 6 others
Phase 2
4 of 15
none open now
Registered
13th of 15
by date
Lead sponsor
15 of 15
AstraZeneca

Among the 15 studies testing tesaglitazar in Diabetes Mellitus, Type 2, this one is the 13th largest by enrollment, is one of 7 that started in 2005, is one of 4 in phase 2, and was the 13th registered.

Diabetes Mellitus, Type 2

10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

None of the 15 studies testing tesaglitazar in Diabetes Mellitus, Type 2 is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →

About tesaglitazar

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 30 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 15 studies testing tesaglitazar in Diabetes Mellitus, Type 2 as a file.
02

Study summary

This is a 16-week randomized, double-blind, parallel-group, multi-center, placebo- and active- (metformin 1.5 g) controlled study of tesaglitazar (1 mg) in patients with type 2 diabetes. After a 1-week enrollment period, a 3 week placebo single blind run in period and 1-week placebo single-blind baseline measurement period, the patients will be given the investigational product for 16 weeks in a double blind fashion. Metformin will be titrated up during the first 3 weeks of the double-blind period. The total study duration, including enrollment, run-in, randomized treatment and follow-up, is 29 weeks.

03

Conditions studied

  • Type 2 Diabetes
04

Who can participate

Ages eligible
30 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provision of a written
  • Men or women who are 30-70 years of age
  • Female patients: , hysterectomized
  • Diagnosed with type 2 diabetes
  • Treated with diet alone or treatment with a single oral antidiabetic agent or low doses of two oral antidiabetic agents

Exclusion criteria

Exclusion Criteria:

  • Type 1 diabetes
  • heart failure Class III or IV
  • Treatment with chronic insulin
  • History of or intolerance to any peroxisome proliferator-activated receptor agonist (like Actos or Avandia), fenofibrate, metformin or 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (statin)
  • History of drug-induced myopathy or drug-induced creatine kinase elevation, liver enzyme elevations, neutropenia (low white blood cells)
  • Creatinine levels above twice the normal range
  • Creatine kinase above 3 times the
  • Received any product in other clinical studies within 12 weeks
  • Any abnormality identified on physical examination, laboratory tests or , which in the judgment of the investigator would compromise the patient's safety or successful participation in the clinical study
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
105 participants

Interventions

06

What researchers measure

Primary outcomes

  1. Whole-body insulin sensitivity by assessing the M value during high (80 mU/m2/min) insulin level euglycemic hyperinsulinemic clamp.

Secondary outcomes

  1. Hepatic and peripheral insulin sensitivity by assessing the M value during low (20 mU/m2/min) insulin level euglycemic hyperinsulinemic clamp.

  2. Basal hepatic glucose output measured by dideuterated glucose in the fasting state and during low insulin level clamp.

  3. Plasma profile of glucose, insulin and lipids after a mixed meal

  4. Calculated insulin secretion

  5. Liver oxidation after a mixed meal

  6. Energy expenditure and substrate metabolism by indirect calorimetry

  7. Body composition using DXA-scan, abdominal fat distribution using magnetic resonance imaging, liver fat and muscle fat content using magnetic resonance spectroscopy

  8. Waist and hip circumference

  9. Laboratory efficacy variables (lipids, inflammatory marker and adipose tissue hormones)

  10. Safety and tolerability of tesaglitazar in patients with type 2 diabetes.

07

Study locations

3 sites
  • Research Site
    Helsinki, Finland
  • Research Site
    Pisa, Italy
  • Research Site
    Oxford, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2005 and a completion of Jul 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 9, 2005
First posted
Dec 12, 2005
Start
Aug 2005
CompletionActual
Jul 2006
Last update
Mar 17, 2008
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 17, 2008, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00263965
Lead sponsor
AstraZeneca
First posted
Dec 12, 2005
Start date
Aug 2005
Completion
Jul 2006
Last update
Mar 17, 2008

Study contacts

AstraZeneca Galida Medical Science Director, MD
study director · AstraZeneca
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tesaglitazar · Metformin

Start the discussion